Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genscript Biotech's Total Assets for the quarter that ended in Jun. 2026 was HK$37,523 Mil.
Warning Sign:
If a company builds assets at 51% a year, faster than its revenue growth rate of 12.1% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Genscript Biotech's average Total Assets Growth Rate was -11.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 55.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 51.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 47.10% per year.
During the past 12 years, Genscript Biotech's highest 3-Year average Total Assets Growth Rate was 80.90%. The lowest was 21.20%. And the median was 55.10%.
Note:
The Net Income data used here is two times the semi-annual (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Genscript Biotech's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Genscript Biotech Total Assets Related Terms
Genscript Biotech Total Assets Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Genscript Biotech's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (HKSE:01548) has a Total Assets of HK$37,523 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Genscript Biotech and its competitors.
Is Genscript Biotech's Total Assets too high?
Genscript Biotech's current Total Assets is HK$37,523 Mil. Overall, Genscript Biotech has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Total Assets compare to VRTX and REGN?
Genscript Biotech's Total Assets of HK$37,523 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current Total Assets is HK$37,523 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (HKSE:01548) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$17.93, compared to a current price of HK$29.36 — trading 63.7% above its estimated fair value. The current Total Assets is HK$37,523 Mil. Genscript Biotech's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Genscript Biotech (HKSE:01548), the current Total Assets is HK$37,523 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (HKSE:01548) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be overvalued.
The current stock price of HK$29.36 is trading 63.7% above its estimated GF Value™ of HK$17.93.
GuruFocus considers Genscript Biotech to be Significantly Overvalued.
Key valuation signals for HKSE:01548:
Total Assets: HK$37,523 Mil
GF Value™: HK$17.93 vs. price of HK$29.36 (63.7% above fair value)
No single metric tells the full story. See the HKSE:01548 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
77GF Score
Get the complete analysis for HKSE:01548
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01548 has been successfully added to your 
